These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2138629)

  • 1. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3.
    Scharla SH; Minne HW; Waibel-Treber S; Schaible A; Lempert UG; Wüster C; Leyendecker G; Ziegler R
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1055-61. PubMed ID: 2138629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).
    Goldray D; Weisman Y; Jaccard N; Merdler C; Chen J; Matzkin H
    J Clin Endocrinol Metab; 1993 Feb; 76(2):288-90. PubMed ID: 7679397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
    Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
    Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone mineral content in premenopausal women treated with gonadotropin-releasing hormone analogue].
    Masahashi T; Negoro Y; Asai M; Suzuki M; Noguchi M; Nakanishi M; Tomita A
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):577-80. PubMed ID: 1619317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
    Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
    N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
    Verrotti A; Chiarelli F; Montanaro AF; Morgese G
    Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Fall PM; Albertsen PC; Dowsett RD; Trahiotis M; Zimmerman J; Ohannessian C; Raisz LG
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4907-13. PubMed ID: 12414849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism].
    Zhang M; He Y; Cao S
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone densitometry as an adjunct to GnRH agonist therapy.
    Cann CE
    J Reprod Med; 1998 Mar; 43(3 Suppl):321-30. PubMed ID: 9564668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration.
    Mann DR; Rudman CG; Akinbami MA; Gould KG
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1263-9. PubMed ID: 1592869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women.
    Ooms ME; Lips P; Roos JC; van der Vijgh WJ; Popp-Snijders C; Bezemer PD; Bouter LM
    J Bone Miner Res; 1995 Aug; 10(8):1177-84. PubMed ID: 8585420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.
    Eckstein N; Foldes J; Feinstein Y; Vagman I; Eshel A; Steinberg R; Statter M; Limor R; Ayalon D
    Maturitas; 1992 Aug; 15(1):25-32. PubMed ID: 1388219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.